ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 556

Defining Flare in Spondyloarthritis : Thresholds of Disease Activity Variations

Marie Godfrin-Valnet1, Marc Puyraveau2 and Daniel Wendling3, 1Rheumatology, CHRU, Besançon, France, 2Investigation Center, CHRU, Besançon, France, 3Service de Rhumatologie, CHU J Minjoz, Besancon, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and spondylarthritis, Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Spondyloarthritis (SpA) activity varies with time and treatment, but to date no clear definition of a flare of the disease is available.

The aim of this study was to evaluate thresholds of disease activity variations using validated composite indexes

Methods:

SpA patients fulfilling ASAS criteria and prospectively followed  with at least two visits were evaluated using BASDAI, ASDAS-CRP and ASDAS-ESR. Patients and physician answered at each visit the question : “do you consider your SpA in a state of flare ?”. Variations of BASDAI and ASDAS between visits were assessed and associated to the change of perception of a flare (yes/no). ROC curves were built to assess thresholds of variation in BASDAI and ASDAS associated with the change Flare : no to yes between visits.

Results:

The patients were issued from a prospective series of 250 SpA. 99 situations with at least 2 visits were analyzed. The main characteristics  of this cohort were : 67 % men , mean age 45 ± 12 years; disease duration : 16 ± 10 y; 84 % HLA-B27 positive; purely axial SpA:  81 %; PASS at baseline : 56 %; mean CRP: 8.6 ± 13.5 mg/l. Mean BASDAI and ASDAS-CRP at baseline were  4.3 ± 2.2 and 2.5 ± 1.1 respectively. The kappa coefficient of agreement between patient and physician for considering a flare was 0.68. The main results of the ROC curves are reported in the table :

Variation of the activity score

Flare considered by

Patient and physician

Flare considered by

Physician

Flare considered by

Patient

BASDAI

Number of 2 visits

AUC

Specificity %

Sensitivity %

2.1

67

0.715

83

59

2.1

97

0.671

82

53

2.1

76

0.694

83

55

ASDAS-CRP

Number of 2 visits

AUC

Specificity %

Sensitivity %

1.3

30

0.740

100

47

0.7

45

0.698

72

59

1.3

34

0.682

100

40

ASDAS-ESR

Number of 2 visits

AUC

Specificity %

Sensitivity %

0.8

28

0.779

91

56

0.8

28

0.779

91

56

0.8

31

0.759

92

50

Conclusion:

According to these results, an increase from a non-flare state of at least 2.1 units in BASDAI, 0.8 units in ASDAS-ESR or 1.3 units in ASDA-CRP is associated to (and may define) a flare, as considered by the patient and the physician.

This is the first study assessing, in current practice, thresholds of variation of activity score associated with a flare in SpA. This may help physicians in the evaluation and management of the patients with SpA.


Disclosure:

M. Godfrin-Valnet,
None;

M. Puyraveau,
None;

D. Wendling,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/defining-flare-in-spondyloarthritis-thresholds-of-disease-activity-variations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology